Mood Changes on GLP-1: Feeling Flat, Low or Unlike Yourself
You might notice it at an ordinary moment. Someone suggests your favourite restaurant and you cannot summon much enthusiasm. That could be about dinner. If you also stop looking forward to seeing friends, reading, music or the weekend, the conversation needs to be wider.
It can be awkward to raise this when people keep telling you how well you look. You are allowed to discuss how you feel without first listing everything treatment has helped. The number on the scales is not a verdict on your emotional wellbeing.
This guide concerns adults using medicines such as semaglutide, tirzepatide or liraglutide. It explains the evidence and helps you prepare a useful conversation. It cannot diagnose depression or decide whether a prescription should change.
What do the FDA and MHRA actually say?
On 13 January 2026, the FDA requested removal of the suicidal-ideation and behaviour warning from Wegovy, Saxenda and Zepbound. Its review found no increased risk. That is a more current position than the early, explicitly preliminary US review from 2024. Read the FDA safety communication.
| Evidence | What was studied | What it can tell us |
|---|---|---|
| FDA trial meta-analysis | 91 placebo-controlled trials; 107,910 participants: 60,338 received a GLP-1 medicine and 47,572 placebo. | No increased risk of suicidal ideation or behaviour, or the other psychiatric events assessed. A pooled safety review does not explain every person's experience of feeling flat. |
| Semaglutide STEP analysis | Post hoc analysis of randomised trials: 3,377 participants in STEP 1–3 over 68 weeks, plus 304 in STEP 5 over 104 weeks. | Did not find increased depression or suicidal ideation/behaviour compared with placebo in the studied population. Important psychiatric exclusions limit who the findings represent. |
The STEP analysis excluded people with recent major depressive disorder, certain other severe psychiatric conditions and a lifetime suicide attempt, among other criteria. Participants generally had few depressive symptoms at baseline. Novo Nordisk funded the research. It was not a trial of semaglutide as a treatment for depression. Read the original JAMA Internal Medicine study.
UK: the MHRA's review, announced on 4 September 2024, also concluded that the available evidence did not support a causal association with depression, suicidal thoughts, suicide or self-injury. The agency continues monitoring. Read the MHRA conclusion.
These findings are reassuring about the risks examined. They do not require you to disregard a new symptom. A prescriber can take your experience seriously while remaining careful about what caused it.
Is emotional flatness the same as quieter food noise?
Quieter food noise concerns thoughts about food. A wider loss of interest or pleasure concerns more of your life. The distinction is useful when describing a problem, though it is not a diagnostic test.
Compare these two statements: “I still enjoy seeing everyone, but I want a smaller dinner,” and “I keep cancelling plans because nothing feels worth doing.” Neither sentence tells a clinician the cause. The second gives them an important reason to ask more questions.
There is no need to adopt the word “anhedonia” to be heard. If you use it, it means reduced ability to experience pleasure. Tell your clinician what that looks like for you: a hobby abandoned, conversations avoided or the feeling that you are merely getting through each day. The National Institute of Mental Health describes loss of interest or pleasure as one possible symptom of depression, alongside others.
Our food-noise guide looks specifically at intrusive thoughts about eating. It does not treat every change in appetite as a mental-health improvement.
What else is worth mentioning at your appointment?
Start with the change you have noticed, then give the surrounding facts. You do not have to arrive with a theory about brain chemicals. An internet explanation about “dopamine switching off” is not an assessment of your situation.
- Timing: when you first noticed the change, and whether it followed starting treatment, a prescribed increase or something else in your life.
- Daily impact: what you have stopped enjoying or find harder to do.
- Eating and physical symptoms: whether meals have become difficult, nausea is persistent or fatigue is limiting your day.
- Sleep: what has changed in your sleeping pattern, rather than simply whether you think you sleep “well”.
- Other treatment: medicines, supplements and recent changes to them, including treatment for an existing mental-health condition.
- Life outside treatment: grief, relationship strain, work pressure, health worries or unwanted comments about your body.
These are details for a conversation, not a checklist that can identify the cause. Several things can happen at once. A difficult week and a new prescription are not mutually exclusive explanations.
When should you ask for help?
Contact your prescriber or primary-care clinician for a new, worsening or persistent mood change, especially if it is affecting work, relationships, sleep or caring for yourself. Do not wait for the next routine medication review if you are struggling now.
Depression is often described using a period of at least two weeks. That is part of clinical assessment, not a rule saying you must wait two weeks to ask for support. Symptoms can deserve attention before then. NIMH explains symptoms and assessment.
If you may act on thoughts of harming yourself, cannot keep yourself safe or are in immediate danger, seek emergency help now: 999 in the UK or 911 in the US, or the nearest emergency department. Stay with someone you trust if you can. This is not a situation to manage through a food diary or an online medication discussion.
For a non-emergency concern, UK readers can contact their GP and the service prescribing the medicine. US readers can contact their primary-care clinician and prescribing service; if a referral is needed, ask about in-network mental-health care. If you already have a mental-health team, include them. Make sure each team knows what the other is prescribing.
What can you say if you are worried about being dismissed?
You can be specific without making an accusation about the medicine:
“My mood has changed since I started treatment. I don't know whether the medicine is the reason, but I am enjoying things less and it is affecting my day. Could we review this, including my eating, sleep and other medicines, and agree what happens next?”
If “everything feels flat” is hard to explain, bring two examples. Perhaps you still meet a friend but would rather go home immediately. Perhaps you have not opened a book you were enjoying. Concrete details often communicate more than a severity number chosen in a hurry.
Ask who will follow up, when, and what should prompt earlier contact. A response of “the studies are reassuring” can be true and still leave your present difficulty unresolved. You can say: “That's helpful to know. What is the plan for the symptoms I'm having?”
What can make ordinary days easier while you get support?
Keep the plan small enough to use. Choose one person you can be honest with and one part of the day you can make less demanding. That might mean accepting a lift, ordering familiar groceries or asking someone to sit with you while you make an appointment.
If a large meal is putting you off social plans, suggest a shorter visit or a different activity. You do not need to give up seeing people because your appetite has changed. Equally, you do not need to turn every walk into a treatment strategy. Spending time with someone can simply be spending time with someone.
Where eating is difficult, our guide to eating enough with a low appetite offers practical starting points. Persistent low intake needs its own discussion with your care team. Food, movement and sleep routines can support daily life; they should not become a reason to delay assessment or blame yourself for feeling unwell.
What else do readers ask about GLP-1 mood changes?
Does feeling flat prove Mounjaro or Zepbound caused it?
No. Timing is useful information, but it does not establish cause. Both brands contain tirzepatide, with different UK and US prescribing contexts. Give your clinician the exact product and a clear account of what changed.
Should you stop treatment if your mood changes?
Ask your prescriber promptly about new or worsening symptoms. This article cannot tell you to stop, continue through a serious problem or alter a dose. If you are unsafe, seek emergency help rather than waiting for a medication decision.
Can a GLP-1 medicine treat depression?
The safety findings discussed here do not establish that. Not increasing a measured risk and treating a mental-health condition are different claims. Continue any agreed mental-health care and discuss proposed changes with the relevant clinician.
What if people say you should be happy about losing weight?
You do not owe them a performance of gratitude. “I'm glad some things have improved, but I'm having a difficult time and getting advice” is enough. You can also choose not to discuss your treatment at all.
© The Reset Edit™ 2026 — Modern Tools + Lifestyle Essentials for Sustainable, Reset Living. All rights reserved.
Information provided is for general lifestyle guidance only and is not medical, financial, or professional advice.
Disclaimer
This article is for general informational purposes only and is not intended to replace medical advice. Always consult a qualified healthcare professional before making changes to your medication, diet, supplements, or exercise routine — especially when using GLP-1 medications such as Ozempic, Wegovy, Zepbound or Mounjaro. The Reset Edit™ provides lifestyle guidance and educational resources only.